MDS Virtual Congress 2021 » Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)

Meeting: MDS Virtual Congress 2021

A phase IV, randomized, double-blind cross-over study comparing the clinical safety, efficacy and duration of abobotulinumtoxinA with onabotulinumtoxinA in adults with upper-limb spasticity: The DIRECTION study

A. Esquenazi, Z. Ayyoub, M. Verduzco-Gutierrez, P. Maisonobe, J. Otto, A. Patel (Elkins Park, USA)

Absence of neutralizing antibody formation during incobotulinumtoxinA treatment of spasticity in botulinum toxin-naïve children with cerebral palsy: pooled analysis of Phase 3 studies

H. Chambers, P. Kaňovský, A. Schroeder, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira, F. Heinen (San Diego, USA)

Cerebellar tDCS for multiple system atrophy cerebellar: Double blinded, randomized, sham-control, cross-over study

JH. Ahn, J. Song, I. Choi, DY. Lee, JW. Cho, WH. Chang, J. Youn (Seoul, Republic of Korea)

Effects of Gandouling Tablets on the Muscle tone and stiffness of patients with Wilson’s disease: a randomized, double-blind, placebo-controlled study

W. Hao (Hefei, China)

Efficacy and safety of incobotulinumtoxinA for upper- or combined upper- and lower-limb spasticity in children/adolescents with cerebral palsy: the XARA study

E. Dabrowski, H. Chambers, D. Gaebler-Spira, M. Banach, P. Kaňovský, A. Hanschmann, M. Althaus, T. Geister, F. Heinen (Royal Oak, USA)

Evaluation of the QTc prolongation risk of deutetrabenazine

F. Schneider, B. Darpo, M. Gutierrez, M. Gordon, L. Rabinovich-Guilatt (Ulm, Germany)

Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8

R. Glanzman, J. Ren, Phd, R. Dewey, Iii, A. Rynders, K. Ho, Phd, R. Dewey, JR. (Holladay, USA)

Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of Phase 3 studies

F. Heinen, P. Kaňovský, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, D. Gaebler-Spira (Munich, Germany)

Long-term safety and activity of ecopipam (ECO), a selective D1 antagonist during treatment of pediatric patients with Tourette Syndrome

R. Chipkin, A. Mahableshwarkar, D. Gilbert (Chicago, USA)

Pilot study to evaluate pimavanserin for the treatment of motor and behavioral symptoms of Tourette syndrome.

A. Billnitzer, J. Jankovic (Houston, USA)

Pooled efficacy and safety analysis of incobotulinumtoxinA for upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS levels IV–V)

P. Kaňovský, D. Gaebler-Spira, A. Schroeder, H. Chambers, E. Dabrowski, T. Geister, A. Hanschmann, I. Pulte, M. Althaus, M. Banach, F. Heinen (Olomouc, Czech Republic)

Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)

D. Claassen, R. Ayyagari, V. Garcia-Horton, S. Zhang, S. Leo (Nashville, USA)

Real-World Evidence Supports use of Transcutaneous Afferent Patterned Stimulation for Tremor Control in Veteran’s Affairs Essential Tremor Patients

K. Colletta, S. Borucki, D. Fujikawa, C. Handforth, A. Phan, A. Killoran, A. Li, K. Rosenbluth (Hines, USA)

The Effect of Electromyography Biofeedback on The Frequency of Clenching on Patients with Bruxism

M. Amine, S. Sawan, U. El-Dakrory (Giza, Egypt)

« View all sessions from the MDS Virtual Congress 2021.